▼ 0.15%
prev close
DaVita is the largest provider of dialysis services in the United States, boasting market share of about 35% when measured by clinics. The firm operates over 3,000 facilities worldwide, mostly in the US, and treats about 280,000 patients globally each year. Government payers dominate US dialysis reimbursement. DaVita receives about two thirds of US sales at government (primarily Medicare) reimbursement rates, with the remainder coming from commercial insurers. While commercial insurers represent only about 10% of US patients treated, they represent nearly all of the profits generated by DaVita in the US dialysis business.
Congressional Trades
1
All tracked trades
Members Trading
1
Unique members
Net Activity
-1
0 buys · 1 sells
Members Who Traded This Stock
1 trade events
| Date | Member | Stock | Type | Amount | Filed | Signal |
|---|---|---|---|---|---|---|
| 2025-09-25 | DVADaVita Inc. Common Stock | Sell | $1,001 - $15,000 | 193d ago | — |
2025-09-25
Julie Johnson
DVA
Amount
$1,001 - $15,000
Filed
193d ago
Recent News
Powered by Polygon.io
Heart Risks Go Beyond the Heart: Don’t Forget to Check Blood Sugar and Kidney Health
R1 Therapeutics launches with oversubscribed $77.5 million Series A financing to advance first-in-class treatment for hyperphosphatemia in patients with chronic kidney disease
3 No-Brainer Warren Buffett Stocks to Buy Right Now
2 Warren Buffett Stocks to Buy Hand Over Fist This Month, and 1 to Avoid
How Berkshire Hathaway Performed During Buffett’s Final Quarter
Trade Timeline
Congressional activity, newest first
Julie Johnson
2025-09-25 · Sale
$1,001 - $15,000